Use of Radiolabeled Compounds in Drug Metabolism and Pharmacokinetic Studies

Citations Over TimeTop 10% of 2012 papers

Abstract

As part of the drug discovery and development process, it is important to understand the fate of the drug candidate in humans and the relevance of the animal species used for preclinical toxicity and pharmacodynamic studies. Therefore, various in vitro and in vivo studies are conducted during the different stages of the drug development process to elucidate the absorption, distribution, metabolism, and excretion properties of the drug candidate. Although state-of-the-art LC/MS techniques are commonly employed for these studies, radiolabeled molecules are still frequently required for the quantification of metabolites and to assess the retention and excretion of all drug related material without relying on structural information and MS ionization properties. In this perspective, we describe the activities of Isotope Chemistry at AstraZeneca and give a brief overview of different commonly used approaches for the preparation of (14)C- and (3)H-labeled drug candidates. Also various drug metabolism and pharmacokinetic studies utilizing radiolabeled drug candidates are presented with in-house examples where relevant. Finally, we outline strategic changes to our use of radiolabeled compounds in drug metabolism and pharmacokinetic studies, with an emphasis on delaying of in vivo studies employing radiolabeled drug molecules.

Related Papers

• → Drug Disposition and Drug–Drug Interactions: Importance of First-Pass Metabolism in Gut and Liver(2009)3 cited
• → Effect of cold exposure on drug action and hepatic drug metabolism in the rat(1972)16 cited
• [Symposium--drug metabolism and drug action. 7. Species differences in drug metabolism].(1970)
• [Symposium--drug metabolism and drug action. 5. Sex difference in drug effects and drug metabolizing enzyme activity in the rat liver microsomes--normal and chemically and physiologically altered states].(1970)
• Using ’Humanized’ TK-NOG mice to predict human drug metabolism and drug-drug interactions(2011)